Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dosage-Finding Study of Adjuvanted Trivalent Influenza Vaccine in Elderly
NCT02126761Phase 1Completed
- Sponsor
- CSL Seqirus
- Start
- Jun 2014
- Primary completion
- Nov 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of adjuvanted trivalent subunit influenza vaccine in influenza (7 arms), sponsored by CSL Seqirus. Primary endpoints: Reactogenicity up to 7 days after vaccination, Unsolicited AEs within 28 days after vaccination and 3 more. Started Jun 2014; status: completed.
02
Drugs
adjuvanted trivalent subunit influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02126761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02126761.